Company profile for Actinogen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to b...
Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
Suite 901, Level 9 109 Pitt Street Sydney NSW 2000
Telephone
Telephone
+61 2 8964 7401
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/18/3207671/0/en/Final-247th-participant-randomized-and-commences-treatment-in-Actinogen-s-XanaMIA-pivotal-phase-2b-3-Alzheimer-s-trial.html

GLOBENEWSWIRE
18 Dec 2025

https://www.globenewswire.com/news-release/2025/09/15/3149989/0/en/Actinogen-achieves-agreement-with-the-FDA-in-a-Type-C-meeting-on-the-manufacturing-clinical-and-nonclinical-activities-required-for-a-future-US-marketing-approval-of-Xanamem-for-Al.html

GLOBENEWSWIRE
15 Sep 2025

https://www.prnewswire.com/news-releases/actinogen-trial-using-intended-commercial-xanamem-tablet-formulation-confirms-target-exposures-in-fed-and-fasted-states-302539899.html

PR NEWSWIRE
27 Aug 2025

https://www.prnewswire.com/news-releases/actinogen-confirms-100th-participant-in-xanamia-phase-2b3-alzheimers-disease-trial-and-interim-analysis-timeline-302494380.html

PR NEWSWIRE
30 Jun 2025

https://www.globenewswire.com/news-release/2025/04/30/3071301/0/en/Actinogen-provides-pivotal-Alzheimer-s-trial-enrolment-update-and-other-business-news.html

GLOBENEWSWIRE
30 Apr 2025

https://www.prnewswire.com/news-releases/actinogen-announces-peer-reviewed-clinical-pharmacology-manuscript-for-xanamem-emestedastat-published-in-clinical-pharmacology-in-drug-development-journal-302374645.html

PR NEWSWIRE
12 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty